Nsclc News Today : Breaking News, Live Updates & Top Stories | Vimarsana

A recap of the days headlines and a look at whats in store for tomorrow. Dealing in u. S. Dollars, currency abroad, business and precious metals, aluminum, steel and coal. And thats only phase one. In less than three months the administration hits irans Oil Production and banking sector. Shannon thank you very much. Those new sanctions kick in against iran at 12 oh one eastern time. Lindsey graham, member of the Senate Armed Services committee joins us now to dig in further. The sanctions kick in and iran is complain about it, senator. Strong message is not just for them but also for our allie...

Consistent with previous observations, overall survival and progression-free survival remained strong at the follow-up point.

Edward S. Kim, MD, MBA, discusses the DESTINY-Lung04 trial, a study evaluating trastuzumab deruxtecan as first-line treatment for patients with HER2 NSCLC.

Experts on HER2 NSCLC discuss the patient populations in which they’d utilize trastuzumab deruxtecan and share their clinical experiences with the therapy.

Alecensa was shown to reduce the risk of disease recurrence or death by 76% versus chemotherapy for patients with ALK-positive non-small cell lung cancer.